Nicholas N. Vahanian
Plus aucun poste en cours
Profil
Nicholas N.
Vahanian was the founder who founded NewLink Genetics Corp.
in 1999 and held the titles of President, Director & Chief Medical Officer from 2015 to 2017.
He also worked as President at Lumos Pharma, Inc. in a former job.
Dr. Vahanian earned an MBA degree from the University of Notre Dame and an undergraduate degree from Virginia Commonwealth University.
Anciens postes connus de Nicholas N. Vahanian
| Sociétés | Poste | Fin |
|---|---|---|
| LUMOS PHARMA, INC. | Fondateur | 11/11/2019 |
| LUMOS PHARMA, INC. | President | 27/09/2019 |
Formation de Nicholas N. Vahanian
| Virginia Commonwealth University | Undergraduate Degree |
| University of Notre Dame | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LUMOS PHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
